OKUR OnKure Therapeutics, Inc.

$3.99

OnKure Therapeutics, Inc. (OKUR) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.4% since its last earnings release on August 4, 2026.

OnKure Therapeutics Beat Consensus Estimates
Tuesday, August 4, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.56)
Rev est $500K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.06

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About OnKure Therapeutics, Inc.

OnKure Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of precision medicines which target biologically validated drivers of cancers. The company is currently developing OKI-219. OnKure Inc., formerly known as Reneo Pharmaceuticals Inc., is based in IRVINE, Calif.

Sector

Healthcare

Industry

Biotechnology